Caspar Friedrich Hausmann founds a pharmacy in St Gallen, Switzerland pioneering iron products.
Sixteen pharmacists establish a joint purchasing centre in Western Switzerland, forming the basis of the future Galenica Ltd.
Pharmacist René Grosclaude founds Vifor Ltd. producing non-prescription medicines.
Ferrum Hausmann, intravenous iron product, developed by Laboratorien Hausmann AG is first introduced in Switzerland. This brand later develops into Venofer®.
Iron (III) polymaltose complex, the future Maltofer®, is introduced in the market.
Galenica acquires Vifor Ltd., taking on their first manufacturing capability.
Galenica acquires Laboratorien Hausmann AG.
Vifor (International) Ltd. is founded and takes over the work of Laboratorien Hausmann in developing new iron products.
Vifor Ltd. invests in new product development for its over-the-counter drugs to support international growth.
FDA (US Food and Drug Administration) approves intravenous iron treatment for the treatment of haemodialysisdependent CKD patients in the US market.
Ferinject® receives regulatory approval in Switzerland and 18 EU countries.
Foundation of Vifor Pharma through the acquisition of Aspreva Pharmaceutical Corporation and integration of Vifor Ltd. and Vifor (International) Ltd.
Acquisition of OM Pharma, a specialist Swiss biotechnology and pharmaceutical company.
Galenica, (55%) and Fresenius Medical Care (45%) form Vifor Fresenius Medical Care Renal Pharma, a new company operating in nephrology.
Injectafer® (US brand name of Ferinject®) receives US FDA approval for Iron Deficiency Anaemia treatment.
Velphoro® receives US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) patients on dialysis.
Velphoro® receives EU marketing authorisation.
Galenica lays foundation for Vifor Pharma to become a stand-alone global specialty pharma company.
Velphoro® receives Swissmedic approval.
Veltassa® receives US FDA approval for the treatment of hyperkalemia.
Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO’s RAYALDEE®.
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets.
ESC guidelines recommend Ferinject®.
Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer’s proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis market.
The US biopharmaceutical company Relypsa was acquired by Galenica and integrated into Vifor Pharma, further strengthening Vifor Pharma’s product Portfolio.
Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases.
Vifor Pharma Ltd.
+41 58 851 80 00